Cartesian Therapeutics(RNAC) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Presented positive topline results from Phase 2b trial of Descartes-08 in patients with myasthenia gravis; Endof-Phase 2 meeting with FDA expected by year-end Dosed first SLE patient in Phase 2 trial of Descartes-08 IND filing for pediatric basket study of Descartes-08 with focus in neurology and rheumatology expected by year-end PIPE financing strengthened balance sheet, with net proceeds expected ...